NASDAQ:SLGL • IL0011417206
The current stock price of SLGL is 92 USD. In the past month the price increased by 52.83%. In the past year, price increased by 1207.72%.
ChartMill assigns a technical rating of 10 / 10 to SLGL. When comparing the yearly performance of all stocks, SLGL is one of the better performing stocks in the market, outperforming 99.86% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to SLGL. SLGL has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months SLGL reported a non-GAAP Earnings per Share(EPS) of -10.1. The EPS decreased by -54.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.68% | ||
| ROE | -10.7% | ||
| Debt/Equity | 0 |
7 analysts have analysed SLGL and the average price target is 112.2 USD. This implies a price increase of 21.96% is expected in the next year compared to the current price of 92.
For the next year, analysts expect an EPS growth of 97.17% and a revenue growth 870.39% for SLGL
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.82 | 985.228B | ||
| JNJ | JOHNSON & JOHNSON | 20.98 | 593.362B | ||
| MRK | MERCK & CO. INC. | 22.66 | 307.597B | ||
| PFE | PFIZER INC | 8.98 | 154.31B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.04 | 125.402B | ||
| ZTS | ZOETIS INC | 18.51 | 56.699B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.72 | 26.207B | ||
| VTRS | VIATRIS INC | 6.35 | 18.503B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 26.18 | 13.107B | ||
| AXSM | AXSOME THERAPEUTICS INC | 201.83 | 8.567B |
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Sol-Gel Technologies Ltd. operates as a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. The firm is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The firm is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
SOL-GEL TECHNOLOGIES LTD
Golda Meir 7
Ness Ziona 7403648 IL
CEO: Alon Seri-Levy
Employees: 34
Phone: 97289313433
Sol-Gel Technologies Ltd. operates as a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. The firm is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The firm is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
The current stock price of SLGL is 92 USD. The price increased by 4.99% in the last trading session.
SLGL does not pay a dividend.
SLGL has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
SOL-GEL TECHNOLOGIES LTD (SLGL) operates in the Health Care sector and the Pharmaceuticals industry.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SLGL.
You can find the ownership structure of SOL-GEL TECHNOLOGIES LTD (SLGL) on the Ownership tab.